Month: May 2020

Reduces infusion time to 2 hours from the conventional 3.5 hours for patients with relapsing or primary progressive multiple sclerosisEMA approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional OCREVUS dosing regimen             Basel, 28 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).AttachmentRoche_mediarelease_Ocrevus_28052020b_EN

May 28, 2020 – Hamilton, BermudaFlex LNG Ltd. (“Flex LNG” or the “Company”) today announced its unaudited financial results for the first quarter and three months ended March 31, 2020Highlights:Revenues of $38.2 million for the first quarter 2020, compared to $52.0 million for the fourth quarter 2019.Net loss of $14.9 million and loss per share of $0.27 for the first quarter 2020, compared to a net income of $23.9 million and earnings per share of $0.44 for the fourth quarter 2019.Average Time Charter Equivalent (“TCE”) rate of $67,740 per day for the first quarter 2020, compared to $94,000 per day for the fourth quarter 2019.Adjusted EBITDA of $27.8 million for the first quarter 2020, compared to $41.6 million for the fourth quarter 2019.Adjusted net income of $9.3 million for the first quarter 2020, compared...

Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer.Basel, 28 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. “As more information about COVID-19 pneumonia becomes available in these unprecedented times, it is more important than ever to work together to fight this disease,” said Levi...

WISeKey is Adapting its R&D and Extended Patents Portfolio to the Post-COVID 19 Economy with Specific Focus on Post-Quantum CryptographyWith more than 25% of its 2019 annual turnover invested in R&D, WISeKey is a significant and recognized contributor to digital trust in an interconnected world. The Company’s recent publication and a conference presentation about post-quantum cryptography illustrates once again that innovation is at the heart of the Company.WISeKey is involved in this NIST PQC (Post-Quantum Cryptography) program with the only objective of providing future-proof digital security solutions based on existing and new hardware architecturesGeneva, Switzerland – May 28, 2020: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity and IoT company, published today a...

Regulated information — Inside informationMay 28, 2020Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of a global offering of ordinary shares represented by American Depository Shares (ADSs) in the United States and certain other countries outside of European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area. The Company anticipates total gross proceeds of approximately $750.0 million (approximately €682.4 million) from the sale of 2,584,138 ADSs at a price of $205.00 per ADS and the sale of 1,074,377 ordinary shares at a price of €186.52 per ordinary share. Each...

RESEARCH TRIANGLE PARK, N.C., May 27, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 18,711,113 shares of its common stock, offered at a price to the public of $4.50 per share. In addition, and in lieu of common stock, BioCryst is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of common stock at a purchase price of $4.49 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering to BioCryst are expected to be $100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst. BioCryst...

GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) — Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $47.00 per share. The gross proceeds to Viela Bio from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $169 million. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 540,000 shares of common stock from the selling stockholders at the public offering price less underwriting discounts and commissions.Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Guggenheim...

ลาสเวกัส, May 28, 2020 (GLOBE NEWSWIRE) — International Spirits & Wellness Holdings, Inc. (OTC: ISWH) (“ISW Holdings” หรือ “บริษัท”) บริษัทหลักทรัพย์การจัดการแบรนด์ระดับโลก ได้ประกาศการเข้าร่วมลงทุนใหม่กับ Bit5ive LLC ซึ่งเป็นผู้นำระดับโลกในการขุดเหรียญคริปโตเคอเรนซี่และโซลูชันการขุดเหรียญที่ล้ำสมัยแบบครบวงจรBit5ive เป็นพันธมิตรด้านการจัดจำหน่ายอย่างเป็นทางการของ Bitmain ผู้ผลิตชิปคอมพิวเตอร์ชั้นนำในอุตสาหกรรมและผู้จัดจำหน่าย Antminer ให้กับกว่า 30 ประเทศในละตินอเมริกา อเมริกากลาง และแคริบเบียน นอกจากนี้ Bit5ive ยังเป็นผู้ผลิตและตัวแทนจำหน่ายของ POD5 และ Power Skid 2.5 ซึ่งเป็นโครงสร้างพื้นฐานที่มีประสิทธิภาพและประสบความสำเร็จมากที่สุดสำหรับฮาร์ดแวร์การขุดเหรียญคริปโต Bit5ive ได้ก้าวมาเป็นหนึ่งในบริษัทที่ใหญ่ที่สุดในสหรัฐอเมริกาในด้านการขุดเหรียญคริปโตเคอเรนซี่และอุตสาหกรรมฟาร์มบิตคอยน์ การร่วมลงทุนกับ ISW Holdings เป็นความสำเร็จครั้งล่าสุดของ...

LAS VEGAS, May 28, 2020 (GLOBE NEWSWIRE) — International Spirits & Wellness Holdings, Inc. (OTC: ISWH) (“ISW Holdings” atau “Perusahaan”), sebuah perusahaan induk manajemen global, mengumumkan bahwa mereka memasuki kerja sama baru dengan Bit5ive LLC, pemimpin global dalam penambangan mata uang kripto dan solusi penambangan turnkey yang inovatif.Bit5ive adalah mitra distribusi resmi Bitmain, produsen cip komputer papan atas terkemuka dan distributor Antminers di lebih dari 30 negara di Amerika Latin, Amerika Tengah, dan Karibia. Bit5ive juga merupakan produsen dan distributor POD5 dan Power Skid 2.5, infrastruktur perangkat keras penambangan kripto yang paling sukses dan efisien. Bit5ive dengan cepat menjadi salah satu perusahaan terbesar di AS dalam penambangan mata uang kripto dan industri farm bitcoin. Kerja sama dengan ISW...